Latest Medical statistics Stories
VANCOUVER, March 18, 2013 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today commented on the United States Food and Drug Administration's (FDA) plan to expedite the approval of new treatments for Alzheimer's disease. As reported by the New York Times, drugs in clinical trials would qualify for approval if people with very early-stage Alzheimer's showed even subtle improvement in memory or reasoning tests. ANAVEX 2-73, the company's lead compound for...
Edgemont Capital serves as exclusive advisor to Miami Research Associates in transaction NEW YORK and MIAMI, Feb. 26, 2013 /PRNewswire/ -- Edgemont Capital Partners, L.P., a boutique investment bank focused on the merger and acquisition advisory needs of healthcare companies, announces the sale of Miami Research Associates ("MRA"), to QPS, LLC. MRA, a multi-therapeutic provider of clinical research services for drug development focused on conducting clinical studies in patient...
BURLINGTON, Mass., Feb. 5, 2013 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that, at a ceremony in London, inVentiv Health Clinical was named "Clinical Company of the Year" by PharmaTimes. "This award recognizes the tremendous value that inVentiv Health Clinical brings to clients," said Paul Meister, Chief Executive Officer of inVentiv Health. "By linking our Clinical...
Research Dynamics Consulting Group, a full service Contract Research Organization (CRO), and ClinROC, LLC, a consulting company of Ophthalmology experts, are announcing a strategic alliance to provide clinical research and product development services for the industry. Rochester, NY, USA (PRWEB) February 04, 2013 Ophthalmology has been shown to be one of the fastest growing fields of clinical research and this alliance aims to meet those needs by providing fast and accurate clinical trial...
BURLINGTON, Mass., Jan. 30, 2013 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial, and consulting services to the healthcare industry, today announced that its existing clinical research organization (CRO), PharmaNet/i3, will be renamed inVentiv Health Clinical. This renaming reflects the closer alignment between the Clinical segment and inVentiv's commercial and consulting services. "As a top global CRO, renaming ourselves inVentiv Health...
PASADENA, Calif., Jan. 29, 2013 /PRNewswire/ -- Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) today announced the company has been in negotiations with an International Bio-Tech Partner in the HIV cure technology sector for joint advanced Research & Development and the partner has agreed to provide the necessary funding for the USA Clinical Trials phases to ultimately achieve FDA approval for the medicines. A senior spokesperson for Immunotech further added, the terms while...
Dr. Brad Vince of Vince & Associates Clinical Research in Kansas City, a leading provider of Phase I-III clinical trial research for the global pharmaceutical and biotech industry, has released a schedule of appearances at a number of conferences and annual meetings in the U.S. and Europe for the first part of 2013. OVERLAND PARK, KS (PRWEB) January 25, 2013 Dr. Brad Vince of Vince & Associates Clinical Research in Kansas City, a leading provider of Phase I-III clinical trial...
SAN FRANCISCO, Jan. 15, 2013 /PRNewswire/ -- goBalto, Inc. announced today the publication of 'Benchmarking the Study Initiation Process' in the January 2013 issue of the Therapeutic Innovation & Regulatory Science journal (formally called the 'Drug Information Journal' published by DIA), a study conducted in collaboration with the Tufts Center for the Study of Drug Development (CSDD). The benchmarking initiative, known as the START (Startup Time And Readiness Tracking) study,...
Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments, according to new research published in the cancer journal Annals of Oncology today (Thursday). In the first study to investigate how accurately outcomes and side-effects are reported in breast cancer trials, researchers at the Princess Margaret Cancer Centre and University of Toronto (Toronto, Canada) found that in a third of all...
SAN FRANCISCO, Jan. 8, 2013 /PRNewswire/ -- goBalto, Inc., a developer of new-generation web clinical research solutions, today announced that INC Research, a therapeutically-focused clinical research organization (CRO), has selected goBalto Tracker 2.0 as its global site activation solution. Tracker is a secure, web-based platform that enables study teams to track and manage site activation activities in clinical trials. "We chose goBalto Tracker as part of our study startup...
